Erythropoietin in chronic renal failure

Valderrábano, Fernando

doi:10.1038/ki.1996.452

Cited by 88 publications

(48 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Deficits in EPO production result in anemia in humans and in animal models. In humans, the most prevalent form of anemia is associated with kidney failure (7). At present, the only treatment for this form of anemia is administration of recombinant EPO via subcutaneous or intravenous injection (8)(9)(10).…”

mentioning

confidence: 99%

Mimicry of erythropoietin by a nonpeptide molecule

Qureshi

Kim

Konteatis

et al. 1999

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

mentioning

confidence: 99%

Mimicry of erythropoietin by a nonpeptide molecule

Qureshi

Kim

Konteatis

et al. 1999

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

“…Date promjene takođe mogu značajno da utiču na kvalitet života. Bubrežni pacijenti, u poređenju sa kontrolnom grupom zdravih vršnjaka, ostvaruju znatno niže postignute rezultate na upitnicima za procjenu kvaliteta života, naročito u domenu fizičkog funkcionisanja, dok su razlike manje izražene u oblasti psihološkog funkcionisanja [10].…”

Section: Mjerni Instrumenti Kvaliteta žIvota Pacijenata Na Hemodijaliziunclassified

Procjena kvaliteta zivota bolesnika na hronicnom programu hemodijalize

Peličić¹,

Ratković²,

Radunović³

et al. 2014

Sestrinska rec

View full text Add to dashboard Cite

UVODTerminalna insuficijencija bubrega je stanje ireverzibilnog gubitka bubrežnih funkcija [1]. Hroničnu bubrežnu bolest karakteriše: sporo napredovanje pogoršanja bubrežne funkcije tokom mjeseci i godina, i smanjenje bubrežne mase [2].Danas se u svijetu ravnopravno koriste sledeće tri metode za zamjenu bubrežne funkcije: hemodijaliza, peritoneumska dijaliza i transplantacija bubrega, koje omogućavaju bolesnicima u terminalnom stadijumu insuficijencije bubrega da produže život bolesnika, i osiguraju bolju rehabilitaciju i bolji kvalitet života. Kvalitet života kod pacijenata na hemodijalizi je teško ispitati, te je potrebno ispitati svakog bolesnika ponaosob, kakav je njegov subjektivni osjećaj, a to se mjeri određenim skalama, tj. instrumentima za procjenu kvaliteta života. Glavni cilj liječenja hemodijalizom nije samo da se omogući život pacijentima bez funkcije bubrega nego da taj produženi život bude obogaćen što većim stepenom rehabilitacije i što boljim kvalitetom. Definicija kvaliteta života WHO definicija HRQoLKvalitet života uslovljen zdravljem se definiše kao individualna procjena bolesnija, koliko bolest i terapija te bolesti utiču na njegov fizički, socijalni ili emocionalni osjećaj "dobrog" [3]. Pojam kvaliteta životaU stručnoj literaturi pojam kvaliteta života uglavnom se vezuje za pojam zdravlja, pri čemu se smatra da ovi koncepti međusobno utiču jedan na drugi i da su veoma bliski. To bi značilo da određivaenje pojma zdravlja u značajnoj mjeri određuje i pojam kvaliteta života.Prema definiciji Svjetske zdravstvene organizacije, zdrav-

show abstract

“…It has been shown that the most frequent and important cause of resistance to EPO is iron deficiency, but there are other less frequent factors [28,177] .…”

Section: Resistancementioning

confidence: 99%

Use of agents stimulating erythropoiesis in digestive diseases

López¹,

Sicilia²,

García³

2009

WJG

View full text Add to dashboard Cite

Anemia is the most common complication of inflammatory bowel disease (IBD). Control and inadequate treatment leads to a worse quality of life and increased morbidity and hospitalization. Blood loss, and to a lesser extent, malabsorption of iron are the main causes of iron deficiency in IBD. There is also a variable component of anemia related to chronic inflammation. The anemia of chronic renal failure has been treated for many years with recombinant human erythropoietin (rHuEPO), which significantly improves quality of life and survival. Subsequently, rHuEPO has been used progressively in other conditions that occur with anemia of chronic processes such as cancer, rheumatoid arthritis or IBD, and anemia associated with the treatment of hepatitis C virus. Erythropoietic agents complete the range of available therapeutic options for treatment of anemia associated with IBD, which begins by treating the basis of the inflammatory disease, along with intravenous iron therapy as first choice. In cases of resistance to treatment with iron, combined therapy with erythropoietic agents aims to achieve near-normal levels of hemoglobin/hematocrit (11-12 g/dL). New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same efficacy and safety.

show abstract

Erythropoietin in chronic renal failure

Cited by 88 publications

References 115 publications

Mimicry of erythropoietin by a nonpeptide molecule

Mimicry of erythropoietin by a nonpeptide molecule

Procjena kvaliteta zivota bolesnika na hronicnom programu hemodijalize

Use of agents stimulating erythropoiesis in digestive diseases

Contact Info

Product

Resources

About